| <P><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">在</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">EULAR 2011</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">年度大会上公布的一项研究数据显示，使用阿达木单抗（</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">Adalimumab</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ADA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，商品名修美乐</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">Humira</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">）</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">+</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">甲氨蝶呤（</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">Methotrexate</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">MTX</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">）进行初始治疗的早期类风湿性关节炎（</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">RA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">）患者，许多患者实现了高水平的疾病控制，还为一些患者提供了改变未来治疗选择的机会。</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial"> <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></P>
<P><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">对</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">1032</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">例发病不足一年的早期活动性</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">RA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">患者进行</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">OPTIMA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">研究，初步评估他们对</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ADA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">（</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">40 mg</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，每两周一次）</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">+MTX</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">联合治疗或</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">MTX</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">单独治疗</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">26</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">周后的治疗响应。结果表明，联合治疗组</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">44%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">的患者</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">26</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">周时达到持续低疾病活动度的目标，</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">MTX</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">单独治疗组则为</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">24%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">。</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ADA+MTX</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">治疗组达到治疗目标的患者为应答者，他们进一步随机继续或退出每两周</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">40 mg</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">的</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ADA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">治疗。</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P>
<P><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">继续治疗的患者保持良好的临床结果、影像学和机能反应直至</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">78</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">周，其中很大比例达到较高的疾病控制指标：</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">77%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">达到</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ACR70</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">86%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">达到</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">DAS</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">缓解（</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">DAS28≤2.6</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">），</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">89%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">无影像学进展。有趣的是，退出治疗的大部分患者也显示出良好的结果：</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">65%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">达到</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ACR70</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">，</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">66%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">达到</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">DAS</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">缓解，</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">81%</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">无影像学进展。中断</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ADA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">治疗患者的试验结果表明，某些患者可以中断治疗，但其长期治疗效果不会受到影响。</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P>
<P><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">EULAR</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">主席、英国利兹教学医院的</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">Paul Emery</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">教授表示，上述</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">OPTIMA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">研究的数据证实了先前的研究结果，首次和继续使用</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">ADA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">治疗早期</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">RA</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">能确保实现并保持较高水平的疾病控制。重要的是，这是首次评估生物因素疾病无控制的全球研究，结果表明，某些患者可成功退出抗肿瘤坏死因子（</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial">TNF</SPAN><SPAN style="COLOR: black; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial">）治疗并保持长期的积极治疗效果，但在这方面还需要进一步研究。</SPAN><SPAN lang=EN-US style="COLOR: black; FONT-FAMILY: Arial"> <o:p></o:p></SPAN></P><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">在整个研究期间其安全性结果与抗</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">TNF</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">治疗活动性</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">RA</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">的安全性大致相同。对</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">850</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例接受</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">ADA</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">治疗的患者进行了不良事件的评估：严重不良事件包括</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">9</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例死亡（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">1.0/100</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">人年，</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">1.0/100PY</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">）和</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">39</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例严重感染（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">4.4/100PY</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">），</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">11</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例恶性肿瘤（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">1.2/100PY</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">）其中包括</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">5</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例非黑色素瘤皮肤癌（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">0.6/100PY</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">），</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">8</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例除结核病外的机会性感染（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">0.9/100PY</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">）和</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">4</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">例确认结核病（</SPAN><SPAN lang=EN-US style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: Arial; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 宋体; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">0.5/100PY</SPAN><SPAN style="FONT-SIZE: 10.5pt; COLOR: black; FONT-FAMILY: 宋体; mso-ascii-font-family: Arial; mso-hansi-font-family: Arial; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-font-kerning: 1.0pt; mso-ansi-language: EN-US; mso-fareast-language: ZH-CN; mso-bidi-language: AR-SA">）。</SPAN> |
